Form 4: 10x Genomics Director John R. Stuelpnagel Reports Acquisition of Class A Common Stock

Director John R. Stuelpnagel reports acquiring 8,649 shares of 10x Genomics Class A Common Stock on June 11, 2024, through restricted stock units.

Summary

• On June 11, 2024, John R. Stuelpnagel, a director of 10x Genomics, Inc. (TXG), acquired 8,649 shares of Class A Common Stock.
• The acquisition was made through restricted stock units (RSUs).
• Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting.
• 1/4th of the RSUs will vest on each quarterly anniversary measured from May 21, 2024, contingent upon continued service as a provider.
• Following the transaction, Stuelpnagel directly owns 344,250 shares of Class A Common Stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock acquisition by a director, which doesn't inherently indicate positive or negative sentiment.

Positives

• The acquisition of shares by a director can be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders and their holdings in the company's stock.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it indicates a director's investment in the company.

Key Dates